Literature DB >> 28935537

Affibody molecules for molecular imaging and targeted drug delivery in the management of breast cancer.

Anindita De1, Gowthamarajan Kuppusamy2, Veera Venkata Satyanarayana Reddy Karri3.   

Abstract

Breast cancer is one of the leading reasons for the morbidity and mortality of cancer related death globally. The modern therapies are basically the combination of the breast-preserving surgeries or ablation with or without node biopsy or destroying the carcinoma cells adjuvant with chemotherapy, radiotherapy, hormonal or biological therapies depending upon the nature of the receptor of the cancerous cells, nature of the lymph node, as well as the tendency of the recurrence. For decade's carcinoma management suffered by the limitation of imagining, targeting and penetrability problem associated with management and cure of this deadly disease leads to unwanted chemo-toxicity and side effects. Alike other antibody mimetics, affibodies are designed with the combinatorial protein engineering approaches which are small and robust protein scaffolds retaining the favorable folding and stability. Affibody is one of the significantly important tools for imaging and diagnosis of the affinity specific over expressed proteins in the breast cancer management. The review summarizes the various affibody strategies uses in the management of breast cancer.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Affibody; Breast cancer; Drug targeting

Mesh:

Substances:

Year:  2017        PMID: 28935537     DOI: 10.1016/j.ijbiomac.2017.09.059

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  4 in total

1.  Application of a Novel 68Ga-HER2 Affibody PET/CT Imaging in Breast Cancer Patients.

Authors:  Haitao Miao; Yuyun Sun; Yizi Jin; Xichun Hu; Shaoli Song; Jian Zhang
Journal:  Front Oncol       Date:  2022-05-30       Impact factor: 5.738

2.  Network-Based Approach to Identify the Antiproliferative Mechanisms of Bruceine D in Breast Cancer From the Cancer Genome Atlas.

Authors:  Saisai Tian; Rui Jing; Weidong Zhang
Journal:  Front Oncol       Date:  2020-07-02       Impact factor: 6.244

3.  The HPV16E7 Affibody as a Novel Potential Therapeutic Agent for Treating Cervical Cancer Is Likely Internalized through Dynamin and Caveolin-1 Dependent Endocytosis.

Authors:  Qingyuan Zhang; Hua Zhu; Zhouying Cui; Yuxiao Li; Jiaying Zhuo; Jingwei Ye; Zhihui Zhang; Zheng Lian; Qianqian Du; Kong-Nan Zhao; Lifang Zhang; Pengfei Jiang
Journal:  Biomolecules       Date:  2022-08-12

4.  Near-Infrared Photoimmunotherapy Using a Small Protein Mimetic for HER2-Overexpressing Breast Cancer.

Authors:  Haruka Yamaguchi; Namfon Pantarat; Takamasa Suzuki; Andreas Evdokiou
Journal:  Int J Mol Sci       Date:  2019-11-20       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.